Merck & Co. Inc. has secured U.S. Food and Drug Administration approval for Keytruda, or pembrolizumab, and Keytruda Qlex, a fixed combination of pembrolizumab and berahyaluronidase alfa-pmph, each used with Padcev, or enfortumab vedotin-ejfv, before and after surgery for adults with muscle-invasive bladder cancer. The expanded indication covers patients regardless of whether they are eligible for cisplatin-based chemotherapy, moving the Merck, Pfizer Inc. and Astellas Pharma Inc. regimen into a broader curative-intent population.
The decision expands a November 2025 approval that was limited to patients who were ineligible for cisplatin. It also gives clinicians a platinum-free perioperative option across the full cisplatin eligibility spectrum, supported by direct Phase 3 evidence against gemcitabine and cisplatin in patients who could otherwise receive the longstanding chemotherapy standard.
That distinction matters because treatment decisions in muscle-invasive bladder cancer have historically begun with a practical question: can the patient tolerate cisplatin? The new label reduces the importance of that divide when selecting between approved perioperative regimens, although it does not remove the need to assess kidney function, neuropathy risk, skin toxicity, metabolic complications, surgical fitness and the capacity to complete prolonged systemic treatment.
Why does the broader FDA label represent more than an incremental bladder cancer expansion?
The latest approval does not simply add another subgroup to an established indication. It creates a single regulatory position for pembrolizumab plus enfortumab vedotin across both cisplatin-eligible and cisplatin-ineligible adults who are candidates for cystectomy, linking evidence from KEYNOTE-B15, also known as EV-304, with the earlier KEYNOTE-905, or EV-303, programme.
For clinicians, the appeal is a treatment pathway that avoids platinum chemotherapy while attacking the disease through two different mechanisms. Pembrolizumab blocks the programmed death receptor-1 pathway, while enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate that delivers a cytotoxic payload to cancer cells. Calling the regimen platinum-free is therefore more precise than calling it chemotherapy-free, because the antibody-drug conjugate still carries a potent cell-killing agent.
The commercial significance is equally clear. Merck is extending the Keytruda franchise from advanced disease into earlier, potentially curable settings, where treatment can continue across the neoadjuvant and adjuvant phases. Pfizer and Astellas are doing the same with Padcev, building on the combination’s established role in locally advanced or metastatic urothelial cancer. Earlier-stage use can expand the addressable population and increase treatment duration, but it also places a higher burden on tolerability, coordination and evidence quality because patients are being treated with curative intent.
How convincing are the KEYNOTE-B15 survival results against cisplatin-based chemotherapy?
KEYNOTE-B15 enrolled 808 previously untreated patients with muscle-invasive bladder cancer who were eligible for cisplatin and candidates for radical cystectomy with pelvic lymph node dissection. Participants were randomly assigned to perioperative pembrolizumab plus enfortumab vedotin or neoadjuvant gemcitabine and cisplatin followed by surgery.
The efficacy results are difficult to dismiss as a surrogate-only win. The combination reduced the risk of disease progression, recurrence or death by 47%, with an event-free survival hazard ratio of 0.53. Median event-free survival had not been reached in the pembrolizumab plus enfortumab vedotin group, compared with 48.5 months in the chemotherapy group. The estimated two-year event-free survival rate was 79.4% with the combination and 66.2% with chemotherapy.
Overall survival strengthened the case. The regimen reduced the risk of death by 35%, producing a hazard ratio of 0.65, while median overall survival had not been reached in either group. The pathological complete response rate was 55.8%, compared with 32.5% for gemcitabine and cisplatin, suggesting that the pre-surgery component achieved substantially deeper tumour clearance at cystectomy.
The trial also has limitations that will shape interpretation. It was open-label, and it was not designed to isolate how much benefit came from treatment before surgery, treatment after surgery or the combined perioperative strategy. The experimental group received both pembrolizumab and enfortumab vedotin before cystectomy, followed by further combination treatment and then additional pembrolizumab, while the control group received neoadjuvant chemotherapy followed mainly by observation. A small proportion of control patients received adjuvant nivolumab, but the trial was not a direct comparison with every contemporary perioperative strategy now available.
Can Keytruda plus Padcev displace cisplatin when other perioperative options already exist?
The approval enters a treatment landscape that has already started moving beyond chemotherapy alone. Durvalumab with gemcitabine and cisplatin before surgery, followed by durvalumab after cystectomy, has been approved for muscle-invasive bladder cancer based on the NIAGARA trial. That option retains cisplatin while adding immunotherapy, whereas pembrolizumab plus enfortumab vedotin removes platinum from the regimen.
This creates a clinically meaningful choice rather than an automatic winner. The Keytruda and Padcev regimen posted a strong event-free survival hazard ratio and a sizeable pathological complete response advantage against chemotherapy, but cross-trial comparisons with the durvalumab regimen cannot determine superiority. Differences in populations, treatment schedules, follow-up, surgical management and endpoint assessment make headline hazard ratios an unreliable substitute for a randomized comparison.
Selection may therefore depend on patient characteristics and institutional experience. A patient with marginal renal function may be unsuitable for cisplatin but still face challenges from enfortumab vedotin-related neuropathy, skin reactions or hyperglycaemia. Another patient may be able to receive cisplatin but prefer, or be clinically directed toward, a regimen with a different toxicity profile. Urologists and medical oncologists will need to coordinate these decisions early because neoadjuvant treatment must support, not compromise, timely curative surgery.
Payers will also compare the cost and duration of two branded therapies against generic chemotherapy-based approaches. A survival benefit supports reimbursement, but the total cost of perioperative combination treatment, toxicity management, infusion visits and post-surgical therapy will remain relevant when health systems develop pathways and prior-authorization rules.
Why could toxicity, discontinuation and surgery timing determine real-world adoption?
The strength of the efficacy data does not make the regimen operationally simple. In KEYNOTE-B15, grade 3 or higher adverse events from any cause occurred more frequently with perioperative enfortumab vedotin plus pembrolizumab than with neoadjuvant chemotherapy. Serious adverse reactions were reported during both the pre-surgery and post-surgery phases, and treatment discontinuations were not rare.
Enfortumab vedotin carries a boxed warning for serious skin reactions and is also associated with peripheral neuropathy, hyperglycaemia and pneumonitis or interstitial lung disease. Pembrolizumab can cause immune-mediated complications affecting multiple organs. These risks are familiar to centres that already use the combination in advanced urothelial cancer, but perioperative treatment creates a different risk calculation because adverse events can delay cystectomy, prevent surgery or complicate recovery.
The trial showed that most patients proceeded to radical cystectomy, although the proportion was slightly lower in the experimental group than in the chemotherapy group. Some patients did not undergo surgery because of adverse reactions, and others experienced treatment-related delays. Those numbers do not erase the survival benefit, but they underline why real-world uptake will depend on disciplined monitoring, rapid toxicity management and close communication between oncology and surgical teams.
Community centres may face a steeper implementation curve than high-volume academic hospitals. The regimen requires confidence in managing both immune-related toxicities and antibody-drug conjugate complications across a treatment course that extends beyond surgery. Adoption may be fastest in centres already familiar with Padcev and Keytruda in metastatic disease, while smaller programmes may initially use more selective patient criteria.
Does Keytruda Qlex materially simplify treatment when Padcev still requires intravenous delivery?
The inclusion of Keytruda Qlex gives Merck a subcutaneous pembrolizumab option alongside intravenous Keytruda. The formulation combines pembrolizumab with berahyaluronidase alfa to enable administration under the skin over approximately one or two minutes, depending on the dosing interval.
That can reduce the administration time for the pembrolizumab component and may improve infusion-chair efficiency. It also gives providers flexibility as Merck shifts part of the Keytruda franchise toward a subcutaneous format. The commercial timing is important because formulation strategy is becoming a larger part of lifecycle management for major immuno-oncology products.
However, Keytruda Qlex does not turn the full regimen into a simple injection-only pathway. Padcev remains an intravenous treatment and is administered on multiple days within each cycle during the combination phases. Patients still need infusion-centre access, laboratory monitoring and toxicity surveillance. The workflow benefit is therefore real but partial, with greater value for chair-time optimization than for eliminating hospital visits.
Hospitals will also need to decide which pembrolizumab formulation fits their economics, staffing and reimbursement environment. Subcutaneous delivery can shorten administration, but drug acquisition, billing, observation procedures and local protocols will determine whether the theoretical efficiency gain produces a meaningful operational advantage.
What does the approval mean for Merck, Pfizer and Astellas investor sentiment?
For Merck, the approval adds another earlier-stage use to a Keytruda franchise that generated more than $8 billion in first-quarter 2026 sales across Keytruda and Keytruda Qlex. The decision reinforces the company’s strategy of extending pembrolizumab into curative-intent settings and combination regimens, although one bladder cancer label expansion is unlikely to alter the investment case by itself given the scale of the franchise.
Merck shares closed at $123.54 on July 10, down 1.22% for the session. The stock had declined 4.65% over five trading days but remained 3.74% higher over one month, within a 52-week range of $76.66 to $130.29. The muted same-day response suggests investors treated the approval as an expected pipeline conversion rather than a surprise capable of immediately changing earnings forecasts.
Pfizer shares closed at $24.17, down 0.33% on the day. The stock was up 1.90% over five trading days but down 7.04% over one month, with a 52-week range of $23.11 to $28.75. That pattern reflects broader investor concerns about post-pandemic growth, patent expirations and the need for acquired oncology assets to deliver. For Pfizer, Padcev is strategically relevant because it helps demonstrate the commercial value of the company’s oncology portfolio following the Seagen acquisition, but investors will look for sustained sales growth rather than regulatory headlines alone.
Astellas shares ended the Tokyo session at 2,142 yen and were almost unchanged over both five trading days and one month, within a 52-week range of 1,398 yen to 2,717 yen. Padcev is one of the Japanese drugmaker’s important growth products, and the broader MIBC label supports a longer commercial runway. Market sentiment will increasingly depend on how quickly perioperative use translates into starts, duration of therapy and international expansion.
What evidence and commercial milestones will determine whether this becomes the preferred regimen?
The next phase will be defined by implementation rather than approval. Clinicians will watch whether the event-free and overall survival advantages remain durable with longer follow-up, whether late toxicities affect quality of life, and how often patients complete the planned post-surgery treatment. The inability of KEYNOTE-B15 to separate the contribution of the neoadjuvant and adjuvant phases will continue to fuel questions about optimal duration.
Comparative treatment selection will become another major issue. Real-world studies may help identify which patients are better suited to pembrolizumab plus enfortumab vedotin, which are better suited to cisplatin plus durvalumab, and whether biomarkers can reduce dependence on broad clinical eligibility rules. The absence of a requirement based on PD-L1 expression or cisplatin eligibility makes the new label commercially broad, but a broad label does not guarantee uniform use.
International regulatory decisions, reimbursement terms and guideline updates will determine the speed of adoption outside the United States. Manufacturers will also need reliable supply and coordinated commercial execution across three companies, particularly as Padcev moves into more treatment settings and Keytruda Qlex introduces another formulation choice.
The FDA approval gives muscle-invasive bladder cancer specialists a survival-backed, platinum-free perioperative regimen for patients on both sides of the cisplatin divide. Its place in care will now be decided by a less glamorous but more consequential test: whether hospitals can deliver the regimen safely, keep patients on schedule for surgery and justify its complexity against increasingly credible alternatives.
